Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02749370 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast
A Phase 4 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
NCT02749370 is a Phase 4 study that has completed, run by Amgen. The registered enrollment target is 80 participants.
The verdict
NCT02749370, a Phase 4 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
Study Summary
To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).
Interventions
- DRUG Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2016-05-18 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02749370
The ClinicalTrials.gov registry entry for NCT02749370 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Etanercept is the first listed.
NCT02749370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02749370 about?
NCT02749370 is a clinical study titled "Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast". To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).
What is the current status of trial NCT02749370?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2016-05-18. Estimated completion is 2017-12-06.
What interventions are being tested in trial NCT02749370?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT02749370?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.